Swedish Orphan Biovitrum returns development rights to Sym001 to Symphogen
Sym001 is currently in clinical phase II for treatment of ITP and in ADP (anti-D Prophylaxis) to prevent HDN. The Sym001 program is based on Symphogen's recombinant polyclonal technology and has been jointly developed since 2006, from early preclinical to its current clinical phase. Swedish Orphan Biovitrum (Sobi) has now decided to opt out of the program to be able to focus fully on its late-stage development pipeline.
"We have appreciated the collaboration with Symphogen on this novel program which may offer patients significant value in the future. With a maturing pipeline we have, however, been forced to prioritize the delivery of our late stage development portfolio", said Peter Edman, CSO of Sobi.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.